New bronchodilation treatment options for patients with COPD

: The main aim of treatment of patients with symptoms of airway obstruction is to improve their quality of life by reducing or removing the main symptoms. To get this effect, you must be able to control the bronchial smooth muscle. This is becoming more possible by the introduction of new inhaled particles, which acting Β2-adrenergic receptors or muscarinic receptors dilate bronchial lumen. New drugs to control Β2-adrenergic receptors exhibit a long duration of action - LABA (long-acting beta-agonist), for example indacaterol, vilanterol or olodaterol can be used once a day, because their action exceeds 24 hours. Similarly, new anticholinergic particles - LAMA (long-acting muscarinic antagonist), for example. tiotropium, glycopyrronium, aclidinium, umeclidinium - also exert their activity by 12-24 hours. Combined preparates LAMA-LABA represent a further significant advance in the treatment, as provided in this form tend to perform better than used alone. In turn, the new bi-functional molecule (dual pharmacophore), which discloses a dual effect by bronchodilating effects by antagonists at muscarinic receptors and agonists at Β2- adrenergic receptors, was described as MABA (muscarinic antagonist and Β2 agonist). The complementary nature of the two receptors was used in construction of this particle. It is expected that the introduction of this new therapy will allow more effective control of airflow obstruction in patients with COPD.